• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

慢性阻塞性肺疾病急性加重

Exacerbations of COPD.

作者信息

Pavord Ian D, Jones Paul W, Burgel Pierre-Régis, Rabe Klaus F

机构信息

Respiratory Medicine Unit, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Division of Clinical Science, St George's, University of London, London, UK.

出版信息

Int J Chron Obstruct Pulmon Dis. 2016 Feb 19;11 Spec Iss(Spec Iss):21-30. doi: 10.2147/COPD.S85978. eCollection 2016.

DOI:10.2147/COPD.S85978
PMID:26937187
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4764047/
Abstract

Exacerbations of chronic obstructive pulmonary disease (COPD) are defined as sustained worsening of a patient's condition beyond normal day-to-day variations that is acute in onset, and that may also require a change in medication and/or hospitalization. Exacerbations have a significant and prolonged impact on health status and outcomes, and negative effects on pulmonary function. A significant proportion of exacerbations are unreported and therefore left untreated, leading to a poorer prognosis than those treated. COPD exacerbations are heterogeneous, and various phenotypes have been proposed which differ in biologic basis, prognosis, and response to therapy. Identification of biomarkers could enable phenotype-driven approaches for the management and prevention of exacerbations. For example, several biomarkers of inflammation can help to identify exacerbations most likely to respond to oral corticosteroids and antibiotics, and patients with a frequent exacerbator phenotype, for whom preventative treatment is appropriate. Reducing the frequency of exacerbations would have a beneficial impact on patient outcomes and prognosis. Preventative strategies include modification of risk factors, treatment of comorbid conditions, the use of bronchodilator therapy with long-acting β2-agonists or long-acting muscarinic antagonists, and inhaled corticosteroids. A better understanding of the mechanisms underlying COPD exacerbations will help to optimize use of the currently available and new interventions for preventing and treating exacerbations.

摘要

慢性阻塞性肺疾病(COPD)急性加重被定义为患者病情持续恶化,超出正常日常变化范围,起病急,可能还需要改变药物治疗和/或住院治疗。急性加重对健康状况和预后有重大且持久的影响,并对肺功能产生负面影响。相当一部分急性加重未被报告,因此未得到治疗,导致预后比接受治疗的患者更差。COPD急性加重具有异质性,已经提出了各种表型,它们在生物学基础、预后和对治疗的反应方面存在差异。生物标志物的识别可以实现基于表型的急性加重管理和预防方法。例如,几种炎症生物标志物可以帮助识别最有可能对口服糖皮质激素和抗生素有反应的急性加重,以及适合进行预防性治疗的频繁急性加重表型患者。降低急性加重的频率将对患者的结局和预后产生有益影响。预防策略包括改变危险因素、治疗合并症、使用长效β2受体激动剂或长效毒蕈碱拮抗剂进行支气管扩张剂治疗以及吸入糖皮质激素。更好地理解COPD急性加重的潜在机制将有助于优化目前可用的和新的预防和治疗急性加重干预措施的使用。

相似文献

1
Exacerbations of COPD.慢性阻塞性肺疾病急性加重
Int J Chron Obstruct Pulmon Dis. 2016 Feb 19;11 Spec Iss(Spec Iss):21-30. doi: 10.2147/COPD.S85978. eCollection 2016.
2
A score to predict short-term risk of COPD exacerbations (SCOPEX).一种预测慢性阻塞性肺疾病急性加重短期风险的评分(SCOPEX)。
Int J Chron Obstruct Pulmon Dis. 2015 Jan 27;10:201-9. doi: 10.2147/COPD.S69589. eCollection 2015.
3
[Acute exacerbations of chronic obstructive pulmonary disease].[慢性阻塞性肺疾病急性加重]
Presse Med. 2009 Mar;38(3):485-95. doi: 10.1016/j.lpm.2008.12.014. Epub 2009 Jan 29.
4
Guideline for the management of chronic obstructive pulmonary disease (COPD): 2004 revision.慢性阻塞性肺疾病(COPD)管理指南:2004年修订版
S Afr Med J. 2004 Jul;94(7 Pt 2):559-75.
5
Impact and prevention of severe exacerbations of COPD: a review of the evidence.慢性阻塞性肺疾病严重加重的影响与预防:证据综述
Int J Chron Obstruct Pulmon Dis. 2017 Oct 5;12:2891-2908. doi: 10.2147/COPD.S139470. eCollection 2017.
6
Comparative efficacy of long-acting muscarinic antagonists in preventing COPD exacerbations: a network meta-analysis and meta-regression.长效毒蕈碱拮抗剂预防慢性阻塞性肺疾病急性加重的比较疗效:一项网状荟萃分析和Meta回归分析
Ther Adv Respir Dis. 2015 Feb;9(1):3-15. doi: 10.1177/1753465814565624.
7
How should we define and classify exacerbations in chronic obstructive pulmonary disease?我们应该如何定义和分类慢性阻塞性肺疾病的加重?
Expert Rev Respir Med. 2013 Apr;7(2 Suppl):33-41. doi: 10.1586/ers.13.16.
8
Real-life data on antibiotic prescription and sputum culture diagnostics in acute exacerbations of COPD in primary care.基层医疗中慢性阻塞性肺疾病急性加重期抗生素处方及痰培养诊断的真实世界数据。
Int J Chron Obstruct Pulmon Dis. 2017 Jan 13;12:285-290. doi: 10.2147/COPD.S120510. eCollection 2017.
9
Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence.基于人群的 1 年匹配队列研究:布地奈德/福莫特罗和丙酸氟替卡松/沙美特罗对慢性阻塞性肺疾病(COPD)患者的相对有效性:对 COPD 加重、急诊就诊和住院、药物使用和治疗依从性的影响。
Clin Ther. 2010 Jul;32(7):1320-8. doi: 10.1016/j.clinthera.2010.06.022.
10
Preventing hospitalization for COPD exacerbations.预防 COPD 加重住院。
Semin Respir Crit Care Med. 2010 Jun;31(3):313-20. doi: 10.1055/s-0030-1254071. Epub 2010 May 21.

引用本文的文献

1
Phenotypes of Exacerbations in Chronic Obstructive Pulmonary Disease.慢性阻塞性肺疾病急性加重的表型
J Clin Med. 2025 Apr 30;14(9):3132. doi: 10.3390/jcm14093132.
2
The Effects of Home High-Flow Nasal Cannula Oxygen Therapy on Clinical Outcomes in Patients with Severe COPD and Frequent Exacerbations.家庭高流量鼻导管吸氧疗法对重度慢性阻塞性肺疾病且频繁急性加重患者临床结局的影响
J Clin Med. 2025 Jan 28;14(3):868. doi: 10.3390/jcm14030868.
3
Validation of Acute Exacerbation of Chronic Obstructive Pulmonary Disease Recording in Electronic Health Records: A Systematic Review.

本文引用的文献

1
Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease.血液嗜酸性粒细胞:慢性阻塞性肺疾病中对超细布地奈德/福莫特罗反应的生物标志物
Am J Respir Crit Care Med. 2015 Aug 15;192(4):523-5. doi: 10.1164/rccm.201502-0235LE.
2
Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials.血液嗜酸性粒细胞计数、加重情况以及慢性阻塞性肺疾病患者添加吸入氟替卡松维兰特罗后的反应:两项平行随机对照试验数据的二次分析。
Lancet Respir Med. 2015 Jun;3(6):435-42. doi: 10.1016/S2213-2600(15)00106-X. Epub 2015 Apr 12.
3
电子健康记录中慢性阻塞性肺疾病急性加重记录的验证:一项系统评价
Chronic Obstr Pulm Dis. 2025 Mar 27;12(2):190-202. doi: 10.15326/jcopdf.2024.0577.
4
Clinical-Epidemiological Profile of Patients With Chronic Obstructive Pulmonary Disease Treated at the Pneumology Outpatient Clinic of a Brazilian University Hospital.巴西一家大学医院肺病门诊治疗的慢性阻塞性肺疾病患者的临床流行病学概况。
Cureus. 2024 Dec 10;16(12):e75451. doi: 10.7759/cureus.75451. eCollection 2024 Dec.
5
An Italian Delphi Consensus on the Triple inhalation Therapy in Chronic Obstructive Pulmonary Disease.意大利慢性阻塞性肺疾病三联吸入疗法德尔菲共识
Multidiscip Respir Med. 2024 Sep 18;19(1):949. doi: 10.5826/mrm.2024.949.
6
AM/PM dosing of LAMA for COPD: a randomized controlled trial protocol using digital recruitment and registries.慢性阻塞性肺疾病长效抗胆碱能药物的早晚给药:一项使用数字招募和登记系统的随机对照试验方案
Front Med (Lausanne). 2024 Aug 6;11:1430169. doi: 10.3389/fmed.2024.1430169. eCollection 2024.
7
Quantifying sustained health system benefits of primary care-based integrated disease management for COPD: a 6-year interrupted time series study.量化基于初级保健的综合疾病管理对 COPD 的持续卫生系统效益:一项 6 年的中断时间序列研究。
Thorax. 2024 Jul 16;79(8):725-734. doi: 10.1136/thorax-2023-221211.
8
Association of blood cadmium concentration with chronic obstructive pulmonary disease progression: a prospective cohort study.血液镉浓度与慢性阻塞性肺疾病进展的关系:一项前瞻性队列研究。
Respir Res. 2024 Feb 17;25(1):91. doi: 10.1186/s12931-024-02726-0.
9
The Role of the Cumulative Illness Rating Scale (CIRS) in Estimating the Impact of Comorbidities on Chronic Obstructive Pulmonary Disease (COPD) Outcomes: A Pilot Study of the MACH (Multidimensional Approach for COPD and High Complexity) Study.累积疾病评定量表(CIRS)在评估合并症对慢性阻塞性肺疾病(COPD)预后影响中的作用:MACH(COPD与高度复杂性多维方法)研究的一项初步研究
J Pers Med. 2023 Nov 30;13(12):1674. doi: 10.3390/jpm13121674.
10
A Serological Neoepitope Biomarker of Neutrophil Elastase-Degraded Calprotectin, Associated with Neutrophil Activity, Identifies Idiopathic Pulmonary Fibrosis and Chronic Obstructive Pulmonary Disease More Effectively Than Total Calprotectin.一种与中性粒细胞活性相关的、由中性粒细胞弹性蛋白酶降解的钙卫蛋白的血清学新表位生物标志物,在鉴别特发性肺纤维化和慢性阻塞性肺疾病方面比总钙卫蛋白更有效。
J Clin Med. 2023 Dec 8;12(24):7589. doi: 10.3390/jcm12247589.
Oxygen therapy in acute exacerbations of chronic obstructive pulmonary disease.慢性阻塞性肺疾病急性加重期的氧疗
Int J Chron Obstruct Pulmon Dis. 2014 Nov 7;9:1241-52. doi: 10.2147/COPD.S41476. eCollection 2014.
4
Characterisation and impact of reported and unreported exacerbations: results from ATTAIN.报告和未报告恶化事件的特征及影响:来自 ATTAIN 的结果。
Eur Respir J. 2014 Nov;44(5):1156-65. doi: 10.1183/09031936.00038814. Epub 2014 Sep 18.
5
Withdrawal of inhaled glucocorticoids and exacerbations of COPD.吸入性糖皮质激素的撤药与 COPD 恶化。
N Engl J Med. 2014 Oct 2;371(14):1285-94. doi: 10.1056/NEJMoa1407154. Epub 2014 Sep 8.
6
Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease.全身用糖皮质激素治疗慢性阻塞性肺疾病急性加重期
Cochrane Database Syst Rev. 2014 Sep 1;2014(9):CD001288. doi: 10.1002/14651858.CD001288.pub4.
7
A clinical in-hospital prognostic score for acute exacerbations of COPD.慢性阻塞性肺疾病急性加重的院内临床预后评分
Respir Res. 2014 Aug 27;15(1):99. doi: 10.1186/s12931-014-0099-9.
8
Characterization of airway inflammation in patients with COPD using fractional exhaled nitric oxide levels: a pilot study.使用呼出一氧化氮分数水平对慢性阻塞性肺疾病患者气道炎症的特征分析:一项初步研究。
Int J Chron Obstruct Pulmon Dis. 2014 Jul 16;9:745-51. doi: 10.2147/COPD.S44552. eCollection 2014.
9
Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis.血液嗜酸性粒细胞指导的泼尼松龙治疗慢性阻塞性肺疾病急性加重:进一步分析
Eur Respir J. 2014 Sep;44(3):789-91. doi: 10.1183/09031936.00062614. Epub 2014 Jun 12.
10
Simvastatin for the prevention of exacerbations in moderate-to-severe COPD.辛伐他汀用于预防中重度慢性阻塞性肺疾病急性加重
N Engl J Med. 2014 Jun 5;370(23):2201-10. doi: 10.1056/NEJMoa1403086. Epub 2014 May 18.